Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. (Q46484712)
Jump to navigation
Jump to search
scientific article published on 14 July 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. |
scientific article published on 14 July 2008 |
Statements
1 reference
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. (English)
1 reference
1 reference
1 reference
Chang-Qi Zhu
1 reference
Keyue Ding
1 reference
Akira Sakurada
1 reference
Jean-Claude Cutz
1 reference
Ni Liu
1 reference
Tong Zhang
1 reference
Paula Marrano
1 reference
Marlo Whitehead
1 reference
Lesley Seymour
1 reference
Frances A Shepherd
1 reference
National Cancer Institute of Canada Clinical Trials Group Study BR.21
1 reference
14 July 2008
1 reference
1 reference
26
1 reference
26
1 reference
4268-4275
1 reference
Identifiers
1 reference
1 reference